Cancer Cell Biology

You have full text access to this OnlineOpen article

Evidence for a pathophysiological role of cysteinyl leukotrienes in classical Hodgkin lymphoma

  1. Frida Schain1,†,*,
  2. Ylva Tryselius2,‡,
  3. Jan Sjöberg1,‡,
  4. Anna Porwit3,
  5. Linda Backman2,
  6. Maria Malec1,3,
  7. Dawei Xu1,
  8. Martina Vockerodt4,
  9. Karl R.N. Baumforth4,
  10. Wenbin Wei4,
  11. Paul G. Murray4,
  12. Magnus Björkholm1,
  13. Hans-Erik Claesson1,2,5

Article first published online: 14 AUG 2008

DOI: 10.1002/ijc.23781

Issue

International Journal of Cancer

International Journal of Cancer

Volume 123, Issue 10, pages 2285–2293, 15 November 2008

Additional Information

How to Cite

Schain, F., Tryselius, Y., Sjöberg, J., Porwit, A., Backman, L., Malec, M., Xu, D., Vockerodt, M., Baumforth, K. R.N., Wei, W., Murray, P. G., Björkholm, M. and Claesson, H.-E. (2008), Evidence for a pathophysiological role of cysteinyl leukotrienes in classical Hodgkin lymphoma. Int. J. Cancer, 123: 2285–2293. doi: 10.1002/ijc.23781

Author Information

  1. 1

    Department of Medicine, Division of Hematology, Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden

  2. 2

    Orexo AB, Berzelius väg 3, Solna, Sweden

  3. 3

    Department of Pathology, Karolinska University Hospital Solna, Stockholm, Sweden

  4. 4

    CRUK Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham, United Kingdom

  5. 5

    Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden

  1. †

    Fax: +46-8-51773054

  2. ‡

    Ylva Tryselius and Jan Sjöberg contributed equally to this work.

*Centre for Molecular Medicine, Division of Hematology, Karolinska University Hospital Solna, SE-171 76 Stockholm, Sweden

Publication History

  1. Issue published online: 12 SEP 2008
  2. Article first published online: 14 AUG 2008
  3. Manuscript Accepted: 28 MAY 2008
  4. Manuscript Received: 20 NOV 2007

Funded by

  • Swedish Cancer Society
  • Stockholm County Council
  • Karolinska Institutet
  • Biolipox AB
  • Orexo AB
  • Leukaemia Research Fund, UK

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (392K)

References

  • 1
    Kuppers R,Rajewsky K. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. Annu Rev Immunol 1998; 16: 471–93.
  • 2
    Hjalgrim H,Askling J,Pukkala E,Hansen S,Munksgaard LFrisch M. Incidence of Hodgkin's disease in Nordic countries. Lancet 2001; 358: 297–8.
  • 3
    Hasenclever D,Diehl V. A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease. N Engl J Med 1998; 339: 1506–14.
  • 4
    Enblad G,Sundstrom C,Glimelius B. Infiltration of eosinophils in Hodgkin's disease involved lymph nodes predicts prognosis. Hematol Oncol 1993; 11: 187–93.
    Direct Link:
  • 5
    Molin D,Edstrom A,Glimelius I,Glimelius B,Nilsson G,Sundstrom CEnblad G. Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. Br J Haematol 2002; 119: 122–4.
    Direct Link:
  • 6
    Maggio E,van den Berg A,Diepstra A,Kluiver J,Visser L,Poppema S. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol 2002; 13 ( Suppl 1): 52–6.
  • 7
    Skinnider BF,Kapp U,Mak TW. Interleukin 13: a growth factor in hodgkin lymphoma. Int Arch Allergy Immunol 2001; 126: 267–76.
  • 8
    Claesson HE,Dahlen SE. Asthma and leukotrienes: antileukotrienes as novel anti-asthmatic drugs. J Intern Med 1999; 245: 205–27.
    Direct Link:
  • 9
    Heise CE,O'Dowd BF,Figueroa DJ,Sawyer N,Nguyen T,Im DS,Stocco R,Bellefeuille JN,Abramovitz M,Cheng R,Williams DL,Jr,Zeng Z, et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 2000; 275: 30531–6.
  • 10
    Lotzer K,Spanbroek R,Hildner MUrbach A,Heller R,Bretschneider E,Galczenski H,Evans JFHabenicht AJ. Differential leukotriene receptor expression and calcium responses in endothelial cells and macrophages indicate 5-lipoxygenase-dependent circuits of inflammation and atherogenesis. Arterioscler Thromb Vasc Biol 2003; 23: 32–6.
  • 11
    Hui KP,Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 1991; 337: 1062–3.
  • 12
    Israel E,Cohn J,Dube L,Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA 1996; 275: 931–6.
  • 13
    Stenke L,Mansour M,Reizenstein PLindgren JA. Stimulation of human myelopoiesis by leukotrienes B4 and C4: interactions with granulocyte-macrophage colony-stimulating factor. Blood 1993; 81: 352–6.
  • 14
    Runarsson G,Liu A,Mahshid Y,Feltenmark S,Pettersson A,Klein E,Bjorkholm M,Claesson HE. Leukotriene B4 plays a pivotal role in CD40-dependent activation of chronic B lymphocytic leukemia cells. Blood 2005; 105: 1274–9.
  • 15
    Ohd JF,Nielsen CK,Campbell J,Landberg G,Lofberg HSjolander A. Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology 2003; 124: 57–70.
  • 16
    Stein H,Delsol G,Pileri S. Classical Hodgkin lymphoma. In: JaffeES,HarrisNL,SteinH,VardimanJW, eds. Tumour of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001. 244–54.
  • 17
    Okuducu AF,Janzen V,Ko Y,Hahne JC,Lu H,Ma ZL,Albers P,Sahin A,Wellman A,Scheinert P,Wernert N. Cellular retinoic acid-binding protein 2 is down-regulated in prostate cancer. Int J Oncol 2005; 27: 1273–82.
  • 18
    Malec M,Soderqvist M,Sirsjo A,MacNamara B,Lewin N,Sjoberg J,Bjorkholm M,Porwit-MacDonald A. Real-time polymerase chain reaction determination of cytokine mRNA expression profiles in Hodgkin's lymphoma. Haematologica 2004; 89: 679–85.
  • 19
    Baumforth KR,Flavell JR,Reynolds GM,Davies G,Pettit TR,Wei W,Morgan S,Stankovic T,Kishi Y,Arai H,Nowakova M,Pratt G, et al. Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells. Blood 2005; 106: 2138–46.
  • 20
    Vockerodt M,Morgan SL,Kuo M,Wei W,Chukwuma MB,Arrand JA,Kube D,Gordon J,Young LS,Woodman CB,Murray PG. The Epstein-Barr virus oncoprotein, latent membrane protein-1 reprograms germinal centre B cells towards a Hodgkin's Reed Sternberg like phenotype. J Pathol, 2008.
    Direct Link:
  • 21
    Lynch KR,O'Neill GP,Liu Q,Im DS,Sawyer N,Metters KM,Coulombe N,Abramowitz M,Figueroa DJ,Zheng Z,Conolly BM,Bai C, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 1999; 399: 789–93.
  • 22
    Takasaki J,Kamohara M,Matsumoto M,Saito T,Sugimoto T,Ohishi T,Ishii H,Ota T,Nishikawa T,Kawai Y,Masuho Y,Isogai T, et al. The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT(2) receptor. Biochem Biophys Res Commun 2000; 274: 316–22.
  • 23
    Ciana P,Fumagalli M,Trincavelli ML,Verderio C,Rosa P,Lecca D,Ferrario S,Parravicini C,Capra V,Gelosa P,Gureeini U,Belcredito S, et al. The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J 2006; 25: 4615–27.
  • 24
    Kanzler H,Hansmann ML,Kapp U,Wolf J,Diehl V,Rajewsky K,Kuppers R. Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin's lymphoma patient. Blood 1996; 87: 3429–36.
  • 25
    Yokomizo T,Izumi T,Chang K,Takuwa Y,Shimizu T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 1997; 387: 620–4.
  • 26
    Devchand PR,Keller H,Peters JM,Vazquez M,Gonzalez FJ,Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 1996; 384: 39–43.
  • 27
    Menard G,Bissonnette EY. Priming of alveolar macrophages by leukotriene D(4): potentiation of inflammation. Am J Respir Cell Mol Biol 2000; 23: 572–7.
  • 28
    Skinnider BF,Kapp U,Mak TW. The role of interleukin 13 in classical Hodgkin lymphoma. Leuk, Lymphoma 2002; 43: 1203–10.
  • 29
    Thivierge M,Stankova J,Rola-Pleszczynski M. IL-13 and IL-4 up-regulate cysteinyl leukotriene 1 receptor expression in human monocytes and macrophages. J Immunol 2001; 167: 2855–60.
  • 30
    Woszczek G,Pawliczak R,Qi HY,Nagineni S,Alsaaty S,Logun C,Shelhamer JH. Functional characterization of human cysteinyl leukotriene 1 receptor gene structure. J Immunol 2005; 175: 5152–9.
  • 31
    Skinnider BF,Elia AJ,Gascoyne RD,Patterson B,Trumper L,Kapp U,Mak TW. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2002; 99: 618–26.
  • 32
    Ohshima K,Akaiwa M,Umeshita R,Suzumiya J,Izuhara K,Kikuchi M. Interleukin-13 and interleukin-13 receptor in Hodgkin's disease: possible autocrine mechanism and involvement in fibrosis. Histopathology 2001; 38: 368–75.
    Direct Link:
  • 33
    Skinnider BF,Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002; 99: 4283–97.
  • 34
    Foss HD,Herbst H,Gottstein S,Demel G,Araujo I,Stein H. Interleukin-8 in Hodgkin's disease. Preferential expression by reactive cells and association with neutrophil density. Am J Pathol 1996; 148: 1229–36.
  • 35
    Jundt F,Anagnostopoulos I,Bommert K,Emmerich F,Muller G,Foss HD,Royer HD,Stein H,Dorken B. Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Blood 1999; 94: 2065–71.
  • 36
    Axdorph U,Porwit-MacDonald A,Sjoberg J,Grimfors G,Ekman M,Wang W,Biberfeld P,Bjorkholm M. Epstein-Barr virus expression in Hodgkin's disease in relation to patient characteristics, serum factors and blood lymphocyte function. Br J Cancer 1999; 81: 1182–7.
View Full Article with Supporting Information (HTML) Get PDF (392K)